1. Biological variation of cardiac myosin-binding protein C in healthy individuals.
- Author
-
Alaour, Bashir, Omland, Torbjørn, Torsvik, Janniche, Kaier, Thomas E., Sylte, Marit S., Strand, Heidi, Quraishi, Jasmine, McGrath, Sam, Williams, Luke, Meex, Steven, Redwood, Simon, Marber, Michael, and Aakre, Kristin M.
- Subjects
BIOLOGICAL variation ,PROTEIN C ,ST elevation myocardial infarction ,COPEPTINS - Abstract
Sample analysis All serum samples were tested in duplicate on the Erenna SP ® sp platform by EMD Millipore Corporation, Hayward California. However, our CV SB A sb % was obtained from duplicates with median cMyC of 4.38 (2.75-5.97) ng/L, which is considerably lower than median cMyC found in patient with adjudicated diagnosis of acute coronary syndrome 237 (71-876) ng/L in the APACE cohort [[6]], and only ~5% of the 99th percentile (derived from patients without coronary artery disease) [[28]]. Analysis, confined to the initial presentation blood sample, showed that cMyC is at least as good as cardiac troponin measured with the leading assays in predicting the diagnosis of AMI, mortality and future cardiovascular events [[6]]. Keywords: biological variation; cardiac myosin-binding protein C; index of individuality; reference change value EN biological variation cardiac myosin-binding protein C index of individuality reference change value 576 583 8 03/11/22 20220301 NES 220301 Introduction Cardiac myosin-binding protein C (cMyC) is a novel biomarker of myocardial injury that was first identified in cardiac venous effluent approximately 10 years ago [[1]]. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF